Co-operation and communication between clinicians and scientists is required to meet the major challenges presented by the diagnosis and therapy of prostate cancer. Molecular oncology is playing an increasing role in this field and has already been instrumental in elucidating many of the basic mechanisms underlying the development and progression of prostate cancer. By understanding these mechanisms, factors which determine whether the tumour will metastasise, such as loss of function of E-cadherin, have been identified and may help the clinician determine which therapeutic strategy is most appropriate for an individual patient. Clinicians also need more sensitive tools to help them diagnose prostate cancer and monitor its progression. The marker DD3/PCA3 shows potential in this respect. Perhaps the most fruitful area for molecular research is in the definition of new therapeutic targets useful in hormone-refractory prostate cancer. In the early stages of development are those agents which target the activation of programmed cell death, inhibition of signal transduction, inactivation of telomerase activity, and differentiation therapy. In order to accelerate the implementation of diagnostic aids and more effective therapeutic strategies for prostate cancer, clinicians must have a greater insight into the molecular mechanisms operating in their patients’ disease and scientists need to understand the clinical problems involved.

Keywords:
Prostate cancer, Molecular oncology, Biological techniques
1.
Giroldi LA, Bringuier PP, Schalken JA: Defective E-cadherin function in urological cancers: Clinical implications and molecular mechanisms. Invasion Metastasis 1994;14:71–81.
2.
Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929–3933.
3.
Bussemakers MJG, van Bokhoven A, Debruyne FMJ: DD3: A new prostate-specific marker, strongly overexpressed in prostatic tumors. J Urol 1997;157:21 [Abs 83].
4.
Lin XS, Denmeade SR, Cisek L, Isaacs JT: Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 1997;33:201–207.
5.
Denmeade SR, Isaacs JT: Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol 1996;35:281–306.
6.
Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA: CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro OFF exhibits anti-tumor activity. Int J Cancer 1997;72:673–679.
7.
Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT: Cell cycle independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 1998;4:1887–1898.
8.
Pai RB, Pai SB, Kukhanova M, Dutschmann GE, Guo K, Cheng YC: Telomerase from human leukemia cells: Properties and its interaction with deoxynucleoside analogues. Cancer Res 1998;58:1909–1913.
9.
Mata JE, Joshi SS, Palen B, Pirruccello SJ, Jackson JD, Ellas N, Page TJ, Medlin KL, Iversen PL: A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt’s lymphoma cells in vitro and in vivo. Toxicol Appl Pharmacol 1997;144:189–197.
10.
Kanazawa Y, Ohkawa K, Ueda K, Mita E, Takehara T, Sasaki Y, Kasahara A, Hayashi N: Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 1996;225:570–576.
11.
Pasquali D, Thaller C, Eichele G: Abnormal level of retinoic acid in prostate cancer tissues. J Clin Endocrinol Metab 1996;81:2186–2191.
12.
Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA: A phase II trial of all-trans-retinoic acid in hormone refractory prostate cancer: A clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol 1997;39:349–356.
13.
De Coster R, Wouters W, Van Ginckel R, End D, Krekels M, Coene MC, Bowden C: Experimental studies with liarozole (R 75,251): An antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol 1992;43:197–201.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.